Durvalumab (MEDI4736 ) plus tremelimumab in resectable, locally advanced squamous cell carcinoma of the oral cavity: a window of opportunity study

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511511-25-00

Acronym

ESR-16-12192

Enrollment

Registered

2024-12-05

Start date

2018-10-12

Completion date

Unknown

Last updated

2024-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

locally advanced squamous cell carcinoma of the oral cavity., Resectable

Brief summary

CD8 infiltration in the tumor

Detailed description

Evaluation by 86Ga-CXCR-4 PET/MR; survival; safety.

Interventions

DRUGIMJUDO 20 mg/ml concentrate for solution for infusion.

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

DRUGCisplatin 1 mg/ml Concentrate for Solution for Infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
CD8 infiltration in the tumor	—

Secondary

Measure	Time frame
Evaluation by 86Ga-CXCR-4 PET/MR; survival; safety.	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026